In a dispute revolving around a fiduciary investment, Vischer successfully represented a Swiss bank. The Vischer team encompassed Thomas Weibel and Raphael Butz (both Litigation and Arbitration, pictured above). Fiduciary investments enable bank customers to
Tags :Vischer
GlycoEra has successfully completed a CHF 45 million Series A financing round, co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics, from which GlycoEra was spun-out, also participated in this round. GlycoEra’s
MiniNaviDent has received an investment by Straumann Holding to further develop and market its Denacam system, a miniaturized dynamic navigation system for dental implants. With the investment, Straumann obtained a 39% stake of mininavident. The two
The full service PR and communications agency Cr Kommunikation “CRK” joins the Myty Group as the second Swiss agency after The House from Zurich. The agency network grows to a total of six agencies in
Bachem Holding, an innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides, has raised CHF 583.5 million through an accelerated bookbuilding process by issuing 750,000 new shares at a placement price of CHF 778 per
CombiGene and Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to the fight against genetic diseases, have entered into an exclusive collaboration and licensing agreement for
Vischer advised an insurance company and its London-based lawyers in an arbitration revolving around a power plant in South America. The dispute between the manufacturer of the plant and the insurer as the legal successor
Nautilus, an innovation specialist in home fitness, has entered into a definitive agreement to acquire Zurich based Vay, a company specialising in computer vision and AI technology solutions and the provider of motion detection and
Tvs Motor Company, an Indian based global two-wheeler and three-wheeler manufacturer and the flagship company of the USD 8.5 billion TVS Group, has agreed on a long-term strategic a partnership with Ego Movement, a fast-growing Swiss
Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor
